VPC-14337

VPC-14337 is an nhibitor of the transcriptional activity of full-length/splice variant Ars.

Product information

CAS Number: 3546-41-6

Molecular Weight: 1151.39

Formula: C75H70N6O6

Synonym:

Pyrvinium pamoate

Pyrvinium embonate

Viprynium embonate

Chemical Name: (E)-2-(2-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)vinyl)-6-(dimethylamino)-1-methylquinolin-1-ium 4,4'-methylenebis(3-hydroxy-2-naphthoate)

Smiles: C[N+]1=C2C=CC(=CC2=CC=C1/C=C/C1C=C(C)N(C2C=CC=CC=2)C=1C)N(C)C.C[N+]1=C2C=CC(=CC2=CC=C1/C=C/C1C=C(C)N(C2C=CC=CC=2)C=1C)N(C)C.[O-]C(=O)C1=CC2=CC=CC=C2C(CC2=C3C=CC=CC3=CC(=C2O)C([O-])=O)=C1O

InChiKey: OOPDAHSJBRZRPH-UHFFFAOYSA-L

InChi: InChI=1S/2C26H28N3.C23H16O6/c2*1-19-17-21(20(2)29(19)24-9-7-6-8-10-24)11-13-23-14-12-22-18-25(27(3)4)15-16-26(22)28(23)5;24-20-16(14-7-3-1-5-12(14)9-18(20)22(26)27)11-17-15-8-4-2-6-13(15)10-19(21(17)25)23(28)29/h2*6-18H,1-5H3;1-10,24-25H,11H2,(H,26,27)(H,28,29)/q2*+1;/p-2

Technical Data

Appearance: Solid Power.

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: Soluble in DMSO

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined.

HS Tariff Code: 382200

How to use

In Vitro:

VPC-14337 (0-500 nM) inhibits proliferation of MCF-7 (luminal), MDA-MB-231 (claudin-low), MDA-MB-468 (basal-like) and SkBr3 (HER2-OE) cells in a dose-dependent manner, with IC50 value of 1170±105.0 nM against MDA-MB-231 cell line. VPC-14337 significantly inhibits self-renewal and proliferation of BCSCs, and suppresses BCSC population with a distinct phenotype. VPC-14337 significantly decreases average expression levels of FZD1, FZD10, WNT1, WNT7B, CTNNB1, MYC, and LRP5 at transcriptional level. Moreover, VPC-14337 also efficiently down-regulates the expression of other stemness genes including ALDH1, CD44 and ABCG2. VPC-14337 blocks colon cancer cell growth in vitro in a dose-dependent manner with great differences in the inhibitory concentration (IC50), ranging from 0.6 to 65 μM for colon cancer cells with mutations in WNT signaling. VPC-14337 decreases messenger RNA (mRNA) and protein levels of known WNT target genes as c-MYC and thereby led to the induction of p21. VPC-14337 ultimately inhibits Wnt signalling despite its lack of efficacy on CK1. VPC-14337 imposes specific toxicity on cardiac fibroblasts in ischemia (IC50=9.5 nM). The cytotoxic effect of VPC-14337 on cardiac fibroblasts specifically under glucose- and glutamine-deficient condition.

In Vivo:

In the xenograft model, VPC-14337 (500 nM)-pretreatment strongly delays tumor size and tumor weight, and the tumor volume is markedly decreased.

References:

1. In the xenograft model, VPC-14337 (500 nM)-pretreatment strongly delays tumor size and tumor weight, and the tumor volume is markedly decreased.
2. Wiegering A, et al. The impact of pyrvinium pamoate on colon cancer cell viability. Int J Colorectal Dis. 2014 Oct;29(10):1189-98.
3. Venerando A, et al. Pyrvinium pamoate does not activate protein kinase CK1, but promotes Akt/PKB down-regulation and GSK3 activation. Biochem J. 2013 May 15;452(1):131-7.

Products are for research use only. Not for human use.